|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 45/06 | (2006.01) | ||
| A61P 19/02 | (2006.01) | ||
| A61P 37/04 | (2006.01) |
| (11) | Number of the document | 1935427 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08001340.2 |
| Date of filing the European patent application | 2001-07-02 | |
| (97) | Date of publication of the European application | 2008-06-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-03-07 |
| (46) | Date of publication of the claims translation | 2018-05-10 |
| (30) | Number | Date | Country code |
| 215913 P | 2000-07-03 | US |
| (72) |
Cohen, Robert, US
Carr, Suzette, US
Hagerty, David, US
Peach, Robert, J., US
Becker, Jean-Claude, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Tirpaus CTLA4 mutantinių molekulių panaudojimas |
| Uses of soluble CTLA4 mutant molecules |
| Payment date | Validity (years) | Amount | |
| 2020-06-26 | 347.00 EUR |